On 10 March 2022, IFPMA Director-General, Thomas Cueni, was invited to address a Panel discussion on ensuring equitable, affordable, timely and universal access for all countries to vaccines in response to the COVID-19 pandemic. The panel discussion took place at the 49th Regular Session of the Human Rights Council.
Read more8 March 2022 – We welcome the Global Pandemic Preparedness Summit on 7-8 March 2022 as a key milestone in rallying efforts to foster development of new vaccines within 100 days of a future pandemic being identified and ensuring their fair and equitable distribution around the world. We hope the Coalition for Epidemic Preparedness Innovations...
Read moreTechnology transfer partnerships have been the cornerstone in the fight against the COVID-19 pandemic, enabling rapid scaling of health innovations but also raising new challenges.
Read more2 March 2022 – As the situation in Ukraine continues to cause unimaginable suffering, our thoughts are with the people in Ukraine. Overcoming the challenges that this unprecedented humanitarian crisis poses for patients is our main concern. We are supporting the efforts of our sister regional organization – EFPIA – to ensure vital medicines reach...
Read moreAs the focus of the global COVID-19 pandemic response shifts downstream from the development and production of vaccines to vaccination campaigns themselves, IFPMA Director-General Thomas Cueni lays out the biopharmaceutical industry’s three new overarching priorities.
Read moreToday’s global health challenges and priorities require innovative approaches, including digital health and data-driven solutions. These solutions have proven their real world value by helping to combat COVID-19. At the same time, the pandemic has reinforced how critical it is to accelerate the digitalization of health systems around the world, and to have appropriate policies and resources that enable digital health benefits to reach all who need them.
Read moreThis paper discusses specifics of ATMPs, where traditional in-country testing is challenging, outlining existing control strategies to detect potential issues, with recommendations to waive in-country testing without compromising product safety, quality and efficacy and in compliance with requirements, i.e., by recognition of certificates from countries with mature National Regulatory Authorities (NRAs).
Read moreTo support the global effort to develop and manufacture safe and effective COVID-19 vaccines and treatments, innovative biopharmaceutical companies will continue to work with all relevant stakeholders on three overarching priorities and supporting activities.
Read moreAs heads of state and government gathered at the 35th African Union Summit (5-6 February 2022), IFPMA as part of the African Medicines Agency Treaty Alliance (AMATA) applauded the momentum reached so far on the ratification and implementation of the AMA.
Read moreThis information is a culmination of clinical development data and post-marketing learnings and data, translated into descriptive text for Healthcare Professionals (HCPs) and in some cases specifically for the patient.
Read moreIn our third Progress Report, Alliance members provide detailed data presenting valuable insights into industry progress on AMR and show some encouraging areas of progress and innovation.
Read moreToday the AMR Industry Alliance released its latest Progress Report, reflecting on collective achievements from the life sciences industry to minimize the spread of antimicrobial resistance (AMR).
Read more